Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: A prescription sequence symmetry analysis

Drug Safety

Volumn 36, Issue 11, 2013, Pages 1079-1086

  Pouwels, Koen B ^a   Visser, Sipke T ^a   Bos, H Jens ^a   Hak, Eelko ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITROFURANTOIN;

ADULT; ANTIBIOTIC THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; DATA BASE; DISEASE COURSE; FEMALE; HUMAN; HYPERTENSION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; URINARY TRACT INFECTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFECTIVE AGENTS, URINARY; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; NETHERLANDS; NITROFURANTOIN; RISK; URINARY RETENTION; URINARY TRACT INFECTIONS;

EID: 84887175696     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0085-z     Document Type: Article

References (33)

1. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941-51.
2. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-64.
3. Oster JR, Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med. 1992;152(4):704-10.
4. Dietz R, Nagel F, Osterziel KJ. Angiotensin-converting enzyme inhibitors and renal function in heart failure. Am J Cardiol. 1992;70(10):119C-25C.
5. Suki WN. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med. 1989;149(3):669-73.
6. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104(16):1985-91.
7. Juhlin T, Bjorkman S, Hoglund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur J Heart Fail. 2005;7(6):1049-56.
8. Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney: a risk-benefit assessment. Drug Saf. 1996;15(3):200-11.
9. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160(10):1465- 70.
10. Beetz R. Mild dehydration: a risk factor of urinary tract infection? Eur J Clin Nutr. 2003;57(Suppl. 2):S52-8.
11. Pouwels KB, Visser ST, Hak E. Effect of pravastatin and fosinopril on recurrent urinary tract infections. J Antimicrob Chemother. 2013;68(3):708-14.
12. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478-84.
13. Pharmacy-dispensing database of IADB.nl (online). Available from URL: http://www.iadb.nl/. Accessed 15 Nov 2012.
14. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf. 2002;11(5):379-84.
15. Leufkens HGM, Urguhart J. Automated pharmacy record linkage in The Netherlands. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2005. p. 311-22.
16. van Pinxteren B, van Vliet SM, Wiersma TJ, Goudswaard AN. Summary of the practice guideline 'urinary-tract infections' (2nd revision) from the Dutch College of General Practitioners (in Dutch). Ned Tijdschr Geneeskd. 2006;150(13):718-22.
17. Akkerman AE, Kuyvenhoven MM, Verheij TJ, van Dijk L. Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates. Pharmacoepidemiol Drug Saf. 2008;17(4):378-83.
18. Ong DS, Kuyvenhoven MM, van Dijk L, Verheij TJ. Antibiotics for respiratory, ear and urinary tract disorders and consistency among GPs. J Antimicrob Chemother. 2008;62(3):587-92.
19. van der Ent M, Remme WJ, de Leeuw PW, Bartels GL. Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril. Cardiovasc Drugs Ther. 1998;12(4):395-403.
20. Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):483-91.
21. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988;296(6632):1313-6.
22. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011;11:110.
23. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281-8.
24. Mannhardt W, Putzer M, Zepp F, Schulte-Wissermann H. Host defense within the urinary tract: II. Signal transducing events activate the uroepithelial defense. Pediatr Nephrol. 1996;10(5):573-7.
25. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999;34(5):795-808.
26. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123(3):133-43.
27. Rossing P, Parving HH, de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy - fact or fiction? Nephrol Dial Transpl. 2006;21(9):2354-7. (discussion 2357-8).
28. De Grauw WJC, Kaasjager HAH, Bilo HJG, et al. Landelijke transmurale afspraak chronische nierschade. Huisarts Wet. 2009;52(12):586-97.
29. Farmacotherapeutisch kompas. Tractus circulatorius - antihypertensive (online). Available from URL: http://www.fk.cvz.nl/default.asp?soort= inleidendetekst&naam=inl%20antihypertensiva/. Accessed 25 Nov 2012.
30. Rutten GEHM, de Grauw WJC, Nijpels G, et al. NHG-standaard diabetes mellitus type 2 (tweede herziening). Huisarts Wet. 2006;49(3):137-52.
31. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82(2):143-56.
32. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf. 2012;21(Suppl. 1):50-61.
33. Venmans LM, Gorter KJ, Rutten GE, Schellevis FG, Hoepelman AI, Hak E. A clinical prediction rule for urinary tract infections in patients with type 2 diabetes mellitus in primary care. Epidemiol Infect. 2009;137(2):166-72.